Dacomitinib, sold under the brand name Vizimpro, is a

medication Medication (also called medicament, medicine, pharmaceutical drug, medicinal product, medicinal drug or simply drug) is a drug used to medical diagnosis, diagnose, cure, treat, or preventive medicine, prevent disease. Drug therapy (pharmaco ...

for the treatment of

non-small-cell lung carcinoma Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitiv ...

(NSCLC). It is a selective and irreversible inhibitor of EGFR. Dacomitinib has advanced to several

Phase III clinical trials The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases ...

. In January 2014, results of the first trials were disappointing, with a failure to meet the study goals, but additional Phase III trials continued. In 2017, results of a trial comparing dacomitinib to

gefitinib Gefitinib, sold under the brand name Iressa, is a medication used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in targe ...

for NSCLC (driven by mutated EGFR) were announced. Dacomitinib was approved for medical use in the United States in September 2018, in Japan in 2019, and in the European Union in 2019; for the treatment of

non-small cell lung cancer Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitiv ...

with

epidermal growth factor receptor The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor (biochemistry), receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligand (biochemistry ...

(EGFR) gene mutation.

References

External links

* {{Portal bar , Medicine Anilines Antineoplastic drugs CYP2D6 inhibitors 1-Piperidinyl compounds Drugs developed by Pfizer Quinazolines Orphan drugs